- Business Wire
New data showed that empagliflozin reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease. These results, from a post-hoc analysis of the landmark EMPA-REG OUTCOMEÂ® trial, were shared as an oral presentation on behalf of Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) at the American Heart Association (AHA) Scientific Sessions 2017 in Anaheim, Calif. and simultaneously published online in the AHAâs journal Circulation.1
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171114005733/en/
âPeripheral artery disease, one of the most common cardiovascular complications associated with type 2 diabetes, increases the risk of death from cardiovascular causes,â said Subodh Verma, M.D., cardiac surgeon-scientist at St. Michaelâs Hospital and professor at the University of Toronto. âThere is an urgent need for treatment options that can improve cardiovascular-related outcomes in people with type 2 diabetes and peripheral artery disease.â
Approximately one in three people with diabetes over the age of 50 have peripheral artery disease, a narrowing of the arteries outside the heart, usually those leading to the arms, legs and feet, due to a buildup of fatty deposits.2 Peripheral artery disease can be life-threatening when blockages restrict circulation causing damage to limbs and can also be associated with damage to vital organs such as the heart, kidneys and brain.3 If peripheral artery disease is not managed properly, it can also lead to amputation, which may result in hospitalization, disability and death.4
At study start, 21 percent of the more than 7,000 EMPA-REG OUTCOMEÂ® trial participants had existing peripheral artery disease. The analysis in this patient population showed that compared with placebo, on top of standard of care:
Overall side effects and serious side effects were balanced between the empagliflozin and placebo groups in adults with and without peripheral artery disease. In the group with peripheral artery disease, lower-limb amputations occurred in 5.5 percent of those treated with empagliflozin and 6.3 percent of those treated with placebo. In the group without peripheral artery disease, lower-limb amputations occurred in 0.9 percent of those treated with empagliflozin and 0.7 percent of those treated with placebo.
âThrough ongoing sub-analyses of the EMPA-REG OUTCOMEÂ® data, we are gaining a better understanding of how empagliflozin may help a wide range of people living with type 2 diabetes and its complications,â said Dr Georg van Husen, Corporate Senior Vice President, Head of the Therapeutic Area CardioMetabolism, Boehringer Ingelheim. âThe data presented and published at the AHA Scientific Sessions showed that empagliflozin reduced the risk for cardiovascular death and kidney disease in this highly vulnerable population of people with type 2 diabetes and peripheral artery disease.â
About Diabetes and Cardiovascular Disease
More than 415 million people worldwide have diabetes, of which 193 million are estimated to be undiagnosed.5 By 2040, the number of people with diabetes is expected to rise to 642 million people worldwide.5 T2D is the most common form of diabetes, responsible for up to 91 percent of diabetes cases in high-income countries.5 Diabetes is a chronic condition that occurs when the body either does not properly produce, or use, the hormone insulin.5
Due to the complications associated with diabetes, such as high blood sugar, high blood pressure and obesity, CV disease is a major complication and the leading cause of death associated with diabetes.6,7 People with diabetes are two to four times more likely to develop CV disease than people without diabetes.7 In 2015, diabetes caused 5 million deaths worldwide, with CV disease as the leading cause.5,7 Approximately 50 percent of deaths in people with T2D worldwide are caused by CV disease.8,9
Having a history of diabetes at age 60 can shorten a personâs lifespan by as much as six years compared with someone without diabetes. And having both diabetes and a history of heart attack or stroke at age 60 can shorten a personâs lifespan by as much as 12 years compared with someone without these conditions.10
Empagliflozin (marketed as JardianceÂ®) is an oral, once daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor approved for use in Europe, the United States and other markets around the world for the treatment of adults with type 2 diabetes.
Inhibition of SGLT2 with empagliflozin in people with type 2 diabetes and high blood sugar levels leads to excretion of excess sugar in the urine. In addition, initiation of empagliflozin increases excretion of salt from the body (i.e. sodium) and reduces the fluid load of the bodyâs blood vessel system (i.e. intravascular volume).Â The glucosuria, natriuresis and osmotic diuresis observed with empagliflozin may contribute to the improvement in cardiovascular outcomes.11
Empagliflozin is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).
About EMPA-REG OUTCOMEÂ®12
EMPA-REG OUTCOMEÂ®Â was a long-term, multicentre, randomised, double-blind, placebo-controlled trial of more than 7,000 people from 42 countries with type 2 diabetes at high risk for cardiovascular events.
The study assessed the effect of empagliflozin (10 mg or 25 mg once daily) added to standard of care compared with placebo added to standard of care. Standard of care was comprised of glucose-lowering agents and cardiovascular drugs (including for blood pressure and cholesterol). The primary endpoint was defined as time to first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke.
Over a median of 3.1 years, empagliflozin significantly reduced the risk of CV death, non-fatal heart attack or non-fatal stroke by 14 percent versus placebo. The risk of CV death was reduced by 38 percent, with no significant difference in the risk of non-fatal heart attack or non-fatal stroke. The overall safety profile of empagliflozin was consistent with that of previous trials.
Please click on the following link for âNotes to Editorsâ and âReferencesâ: http://www.boehringer-ingelheim.com/AHA-2017-Empagliflozin.
El cocinero francés Paul Bocuse ha fallecido en París a la edad de 91 años, según informan varios medios.
El presidente del Gobierno, Mariano Rajoy, ha considerado que la decisión de la agencia de calificación de riesgo Fitch de subir la nota de …
Los jugadores del Real Madrid, ajenos a la mala racha de juego y resultados del equipo de Zinedine Zidane, han puesto de manifiesto el buen …
Zinedine Zidane, entrenador del Real Madrid, dejó claro que entre su club y él no hay ningún problema ni opiniones diferentes y desveló …
El asteroide mediano 2002 AJ129, conocido por su alta velocidad entre los objetos cercanos a la Tierra registrados, pasará cerca de nuestro …
El presidente del Comité Olímpico Internacional (COI), Thomas Bach, ha anunciado este sábado que el organismo ha aprobado que Corea del …
Antoine Griezmann se ha convertido en el gran objetivo del Barcelona para la próxima temporada. El atacante francés es uno de los deseos de …
Científicos de la Universidad de Maryland (Estados Unidos) han descubierto que el virus de la gripe puede propagarse más fácil de lo que …
El número 68262 ha sido agraciado con el primer premio de la Lotería Nacional del sábado 20 de enero de 2017, premiado con 1.000.000 de …
El secretario de Organización de Podemos, Pablo Echenique, ha advertido este sábado que "la corrupción del Partido Popular no solamente …
Noticias más leidas
Noticias más leidas
Noticias más leidas
Noticias más leidas
Noticias más leidas
El mapa de los whiskies más caros